First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors.
S. O. Dolly
No relevant relationships to disclose
J. Albanell
Consultant or Advisory Role - Roche
F. Kraeber-Bodere
Consultant or Advisory Role - Roche
Honoraria - Roche
U. Banerji
No relevant relationships to disclose
R. Bahleda
No relevant relationships to disclose
M. Martinez Garcia
No relevant relationships to disclose
Z. X. Xu
Employment or Leadership Position - Roche
Stock Ownership - Roche
E. Guarin
Employment or Leadership Position - Roche
J. Tessier
Employment or Leadership Position - Roche
E. Shochat
Employment or Leadership Position - Roche
J. Deutsch
Employment or Leadership Position - Roche
Stock Ownership - Roche
S. Blotner
Employment or Leadership Position - Roche
V. Meresse
Employment or Leadership Position - Roche
J. Soria
Honoraria - Roche